- Home
- ESLA vs COHN Comparison
ESLA vs COHN Comparison
Compare ESLA & COHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESLA | COHN |
|---|---|---|
| Founded | 2021 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.9M | 54.3M |
| IPO Year | N/A | 2003 |
Fundamental Metrics
Financial Performance| Metric | ESLA | COHN |
|---|---|---|
| Price | $1.68 | $23.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 163.3K | 27.2K |
| Earning Date | 05-26-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 4.28% |
| EPS Growth | N/A | ★ 5537.50 |
| EPS | N/A | ★ 4.35 |
| Revenue | N/A | ★ $275,564,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.45 |
| Revenue Growth | N/A | ★ 246.19 |
| 52 Week Low | $0.78 | $7.78 |
| 52 Week High | $3.15 | $32.60 |
Technical Indicators
Market Signals| Indicator | ESLA | COHN |
|---|---|---|
| Relative Strength Index (RSI) | 51.74 | 66.66 |
| Support Level | $1.48 | $17.09 |
| Resistance Level | $2.07 | $25.07 |
| Average True Range (ATR) | 0.18 | 1.65 |
| MACD | -0.03 | 0.29 |
| Stochastic Oscillator | 16.00 | 80.80 |
Price Performance
Historical ComparisonAbout ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About COHN Cohen & Company Inc.
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.